国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產(chǎn)品 » 穩(wěn)定細(xì)胞系 » Human Recombinant κ-Opioid Receptor OPRK1 Stable Cell Line
CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.

CHO-K1/OPRK1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
M00290
詢價(jià)

聯(lián)系我們
Product Description Recombinant CHO-K1 cells stably overexpress human opioid receptor kappa 1 (OPRK1) on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with U-50488 in CHO-K1/OPRK1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/OPRK1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 42.36 nM.

  • CHO-K1/OPRK1/Gα15 Stable Cell Line
  • CHO-K1/OPRK1/Gα15 Stable Cell Line

    Figure 1. U-50488-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/OPRK1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with OPRK1 agonist, U-50488. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of U-50488 (mean ± SEM, n = 3). The EC50 of U-50488 on CHO-K1/OPRK1/Gα15 cells was 11.07 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response.
    Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級(jí)的網(wǎng)站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 天津市| 军事| 农安县| 宁蒗| 白河县| 循化| 黔东| 岚皋县| 阳江市| 武鸣县| 南投市| 临潭县| 红桥区| 洛隆县| 临高县| 松滋市| 雷波县| 乌海市| 祁门县| 古交市| 颍上县| 横山县| 都兰县| 洞口县| 泽库县| 桐梓县| 北碚区| 电白县| 赤壁市| 天等县| 涡阳县| 三都| 太和县| 布拖县| 九寨沟县| 刚察县| 盐津县| 东城区| 徐闻县| 华池县| 武胜县|